Showing
1 - 2
results of
2
for search '
Dingemans, A.-M.C
'
Skip to content
Home
High Impact Articles
Search Options
UiTM Open Access
Search by UiTM Scopus
Advanced Search
Search by Category
Discovery Service
Sources
Jawi Collection
UiTM Journals
List UiTM Journal in IR
Statistic
About
Open Access
Creative Commons Licenses
COKI | Malaysia Open Access
Report Technical
User Guide
Contact Us
Search Tips
FAQs
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Author
Dingemans, A.-M.C
Showing
1 - 2
results of
2
for search '
Dingemans, A.-M.C
'
, query time: 2.50s
Refine Results
Sort
Relevance
Date Descending
Date Ascending
Call Number
Author
Title
1
Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inh...
by
Abtahi, S.
,
Croes, S.
,
de Vries, F.
,
Dingemans
,
A
.-
M.C
,
Driessen, J.H.M
,
Klungel, O.H
,
Souverein, P.
,
van Geel, R.
,
van Veelen, A.
Published 2022
Call Number:
Loading...
Located:
Loading...
View Fulltext in Publisher
Article
2
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
by
de Langen, A.J
,
Dingemans
,
A
.-
M.C
,
Hashemi, S.M.S
,
Hendriks, L.E.L
,
Hiddinga, B.I
,
Hijmering Kappelle, L.B.M
,
Hiltermann, T.J.N
,
ter Elst, A.
,
van den Heuvel, M.M
,
van der Leest, C.
,
van der Wekken, A.J
,
van Veggel, B.
,
Zwierenga, F.
Published 2022
Call Number:
Loading...
Located:
Loading...
View Fulltext in Publisher
Article
Search Tools:
Get RSS Feed
—
Email this Search
Related Subjects
Tyrosine kinase inhibitors
CPRD
Epidermal growth factor receptor
Exon 20 mutation
Immune checkpoint inhibitors
Lung cancer
Non-small cell lung cancer
Osimertinib
Study eligibility
Loading...